Opioid agonist/antagonist has a big impact in phase IIb trial ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...

Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures ...

Breakthrough Mount Sinai study is the first to link this symptom to the novel synthetic drug in opioid overdose; findings can ...

DURHAM, NC and LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, today announced the expansion of its Xenon MRI ...

Bouraïma, F. , Ametonou, C. , Agbokponto, A. , Hounlelou, V. and Flatin, M. (2026) Tracheotomy in an African Hospital Setting ...

Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

Epinephrine is a commonly used agent for a variety of indications and clinical scenarios within the emergency department. It is commonly administered during cardiopulmonary arrest and serves as an ...

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj ® (revumenib) ...

When most people think of concussion, the first type of patient that comes to mind is a youth athlete. However, concussion is ...

Blood lactate is influenced by a wide range of metabolic processes. Blood lactate—much like central venous pressure—can ...